Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility

Gerry Z. M. Ma1,2, Jim Stankovich3, The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene),4 Trevor J. Kilpatrick1,2, Michele D. Binder1,2,∗, Judith Field1,2,∗.

1 Multiple Sclerosis Division, Florey Neuroscience Institutes, University of Melbourne, Melbourne, Victoria, Australia, 2 Centre for Neuroscience, University of Melbourne, Melbourne, Victoria, Australia, 3 Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia

Abstract

Multiple sclerosis (MS) is a debilitating, chronic demyelinating disease of the central nervous system affecting over 2 million people worldwide. The TAM family of receptor tyrosine kinases (TYRO3, AXL and MERTK) have been implicated as important players during demyelination in both animal models of MS and in the human disease. We therefore conducted an association study to identify single nucleotide polymorphisms (SNPs) within genes encoding the TAM receptors and their ligands associated with MS. Analysis of genotype data from a genome-wide association study which consisted of 1618 MS cases and 3413 healthy controls conducted by the Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) revealed several SNPs within the MERTK gene (Chromosome 2q14.1, Accession Number NG_011607.1) that showed suggestive association with MS. We therefore interrogated 28 SNPs in MERTK in an independent replication cohort of 1140 MS cases and 1140 healthy controls. We found 12 SNPs that replicated, with 7 SNPs showing p-values of less than 10−5 when the discovery and replication cohorts were combined. All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility.

Introduction

Multiple sclerosis (MS) is a chronic demyelinating and inflammatory disease of the central nervous system (CNS), affecting mainly individuals of European ancestry [1]. The disease is characterised by CNS demyelination, loss of oligodendrocytes, inflammation, as well as neurodegeneration. Susceptibility to MS is thought to involve a complex interplay of genetic and environmental factors, with the HLA-DRB1*1501-DQB1*602 (HLA-DR15) haplotype in the major histocompatibility complex (MHC) being the predominant genetic risk factor [2,3]. Other genetic associations have been observed and replicated in IL7R [2], IL2RA [2], CLEC16A [4,5], CD226 [5], CD6 [6], IRF8 [6], TLR8 [6], STAT3 [7], KLF21B [8], TMEM39A [8] and TYK2 [9].

The TAM receptors (TYRO3, AXL and MERTK) comprise a family of structurally related receptor tyrosine kinases that have two identified ligands: GAS6 and protein S [10,11,12]. TAM receptor signaling has been implicated in several biological processes, including cell survival and proliferation [13,14,15,16], immune regulation [17,18,19] and phagocytosis of apoptotic cells [19,20,21]. As these are all key processes involved in demyelination, several recent studies have examined the role of these receptors in animal models of MS, as well as in the human disease.

Previous work in our laboratory examined the course of cuprizone-induced demyelination in mice lacking the TAM receptor ligand GAS6. Cuprizone is a neurotoxin that when incorporated into the feed of mice, induces specific and focal T cell-independent demyelination within the CNS, particularly in the corpus callosum [22,23,24]. Following 3 weeks of cuprizone-challenge we observed greater demyelination, which corresponded with increased oligodendrocyte loss and microglial activation in the absence of GAS6 compared with wild-type mice [25]. In a separate study, AXL receptor knockout mice displayed an overall reduction in myelination following 6 weeks of cuprizone-challenge, as well as a delay in microglial activation and the clearance of
myelin debris and apoptotic cells [26]. The apparent differences between the phenotypes of the ligand and single receptor knockout mice during cuprizone-challenge highlights the complexity of TAM receptor signaling; but more importantly, these studies clearly show that loss of TAM receptor signaling is accompanied by increased demyelination in the cuprizone model.

The studies by Binder et al. [25] and Hoehn et al. [26] have focused on experimental animals, but a recent study has implicated the TAM receptors as important players in human MS as well. In a study of human MS lesions, levels of soluble forms of the TAM receptors, which can act as decoy receptors for the membrane-bound receptors, were compared in chronic silent MS lesions, chronic active MS lesions and healthy controls. It was found that levels of soluble AXL were higher in chronic silent lesions, while levels of soluble MERTK were higher in chronic active lesions compared with controls [27]. These elevated levels of soluble AXL and MERTK also correlated with low levels of GAS6 within the lesions [27], suggesting that loss of TAM receptor signaling may prolong MS lesion activity. Taken together, these studies implicate TAM receptor signaling as playing a key role in several processes affecting the outcome of demyelination in both animal models as well as human MS.

Given the aforementioned results, we hypothesized that polymorphisms in the TAM receptor or ligand genes would be associated with MS and thus also be involved in the aetiology of the disease. In a recent genome-wide association study (GWAS) conducted by the Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) [28], several single nucleotide polymorphisms (SNPs) within the MERTK gene (Chromosome 2q14.1, Accession Number NG_011607.1) showed suggestive association with susceptibility to MS, while SNPs within the TYRO3, AXL, GAS6 and PROS1 genes did not show any suggestive associations. We therefore conducted a replication study with a candidate gene approach focusing on the MERTK gene as a novel risk gene involved in MS susceptibility.

Methods

Study subjects

The Melbourne Health Human Research Ethics Committee and the Australian Bone Marrow Donor Registry Ethics Committee granted approval for this research. Written consent was given by the subjects for their information to be stored in the study database and used for research.

Genotype data from a GWAS conducted by the ANZgene Consortium [28] was used as a discovery dataset to search the five TAM receptor and ligand genes for SNPs that showed suggestive association with MS susceptibility. Following quality control as outlined in the ANZgene GWAS [28], this dataset consisted of 1618 MS cases of European ancestry from Australia and New Zealand, and 3413 healthy controls from Australia, the UK and the US. All GWAS subjects were genotyped using Illumina arrays (Illumina, California, USA). Genomic DNA from all subjects was extracted under conditions recommended by the manufacturer (Sequenom, California, USA). Analyses were performed to impute the most likely values of SNPs that were genotyped in both the GWAS and replication cohorts, association analysis was performed using the

Table 1. Replication sample data.

| MS patients (n = 1140) | Controls (n = 1140) |
|-----------------------|---------------------|
| Mean age of onset ± standard deviation: | 33.85±10.14 | N/A |
| Sex:                  |                     |
| Female                | 816                 | 669 |
| Male                  | 247                 | 450 |
| Unknown               | 77                  | 21  |
| MS disease course:    | N/A                 |
| RRMS                  | 632                 |     |
| SPMS                  | 369                 |     |
| PPMS                  | 58                  |     |
| Single                | 1                   |     |
| Unknown               | 80                  |     |
| MS: multiple sclerosis; N/A: not applicable; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary-progressive multiple sclerosis; PPMS: primary-progressive multiple sclerosis; Single: first demyelinating event. ¹Age information only available for 1069 MS patients and the mean is calculated as such. ²http://13717/1journal.pone.0016964.0001 |

controls were from the Australian Bone Marrow Donor Registry with no history of clinically isolated syndrome or MS at the time of collection. All samples were obtained from individuals of European ancestry from Australia and New Zealand.

SNP selection

Of the top 7 directly genotyped SNPs in TAM receptor and ligand genes in the ANZgene GWAS, 6 were in the MERTK gene (Table S1). We therefore took a candidate gene approach focusing on MERTK. Using the total of 22 directly genotyped SNPs in the MERTK gene as proxies, non-genotyped SNPs that were tagged in the GWAS dataset were imputed using Beagle [29]. Based on this information, we selected 28 SNPs that showed suggestive association with MS to interrogate in the replication phase. These included the top 6 genotyped SNPs in the ANZgene GWAS, plus 22 imputed SNPs that showed suggestive association with MS.

Imputation

Imputation of tagged, un-genotyped SNPs in the GWAS cohort was performed with Beagle v3.2.0 (http://faculty.washington.edu/browning/beagle/beagle.html) [29] using the default settings. Analyses were performed to impute the most likely values of missing genotypes, and to calculate posterior genotype probabilities at all HapMap SNPs. To do this, data from unphased HapMap phase II CEU (USA residents of northern and western European ancestry) individuals (release 24, build 36, forward strand) was used as a reference panel.

Statistical analysis

For SNPs that were genotyped in both the GWAS and replication cohorts, association analysis was performed using the
–assoc command in PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) [30].

For SNPs that were imputed in either the GWAS or replication subjects, posterior allele dosages were used to perform the association analysis. The posterior allele dosage is twice the posterior genotype probability of the AA genotype plus the posterior genotype probability of the AB genotype (where A represents one of the alleles for the marker and B the other allele). Linear regression of allele dosages on case-control status was performed to test for association, with adjustment for sample group (discovery/replication) in the combined dataset.

**Linkage disequilibrium analysis**

To investigate linkage disequilibrium (LD) between SNPs, data from Hapmap phase II CEU individuals (release 24, build 36, forward strand) was analysed using Haploview v4.2 (http://www.broadinstitute.org/haploview) [31].
| SNP ID    | Chr | Position1 | Gene    | Major Allele | Minor Allele | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Imp | MAF cases | Gen/Ip...
Hardy-Weinberg equilibrium analysis

Hardy-Weinberg equilibrium of SNPs was determined by using the –hardy command in PLINK v1.07. SNPs in significant Hardy-Weinberg disequilibrium ($p<10^{-7}$) in control groups were excluded from further analysis.

**Results and Discussion**

Our discovery dataset consisted of genotype data of 1618 MS cases and 3413 controls of European ancestry from a recent GWAS [28]. Of the top 7 directly genotyped SNPs in genes encoding TAM receptors and their ligands that showed suggestive $p$-values for association with MS in the discovery dataset, 6 were in the **MERTK** gene (Chromosome 2q14.1, Accession Number NG_011607.1) (Table S1). Based on association analysis of directly genotyped and imputed SNPs in the discovery dataset, we conducted a replication study with a candidate gene approach focusing on 28 SNPs within the **MERTK** gene. In our independent replication cohort, 12 of the 28 interrogated SNPs replicated, with association $p$-values of less than 0.05 and odds ratios going in the same direction as in the discovery dataset (Fig. 1A, Table 2). All 12 replicated SNPs had $p$-values of less than $10^{-4}$ when the discovery and replication cohorts were combined. Notable SNPs with combined $p$-values of less than $10^{-5}$ were rs867311, rs12477716, rs17835603, rs4278932, rs4528767, rs17174870 and rs1516629. Linkage disequilibrium analysis showed all 12 replicated SNPs to be in strong LD with each other, with $D^{'^2}=1$ and $r^{'^2}>0.95$ for all pairs of SNPs (Fig. 1B).

We included the top 6 genotyped SNPs from the discovery dataset with $p$-values of less than 0.05 in the 28 SNPs that were genotyped in our replication cohort. Of these SNPs, only rs11884641 replicated, with the other 5 showing $p$-values of greater than 0.05 in the replication cohort (Table 2).

Although the SNPs interrogated in this study do not reach the level of genome-wide significance ($p<5\times10^{-8}$), our study nevertheless identifies 12 SNPs that replicate in two independent cohorts of MS cases and controls, and that reach a level of significance required for a candidate gene approach. This provides strong evidence that the **MERTK** gene is associated with MS susceptibility. The 12 replicated SNPs are all common variants; although all are intronic and in strong LD with each other, they may be tagging potentially rare causal variants within coding regions of the gene. Fine mapping of the **MERTK** gene and interrogation of different populations with larger sample sizes may aid in determining the exact causal variants. As MS is a genetically complex disease, the **MERTK** gene may also represent one of many disease loci that confer susceptibility to MS when present in combination.

The TAM receptors have been shown to be major players in regulation of the immune response [17,18,19]. Triple TAM receptor mutants develop widespread autoimmunity, with increased circulating levels of autoantibodies [17]. The autoimmune phenotype showed a gene dosage effect, with less severe autoimmunity in mice deficient for two TAM receptors, and an even milder, although still pronounced effect in mice deficient for just one TAM receptor [17]. The role of **MERTK** in regulating the immune response has been extensively examined, especially in relation to its role in the phagocytosis of apoptotic cells. It has been shown that **MERTK** knockout mice have macrophages deficient in their ability to clear apoptotic cells, leading to the development of a progressive systemic lupus erythematosus-like phenotype [20,32]. In the immune system, **MERTK** has also been implicated in regulation of dendritic cell activation [33], T cell selection and tolerance [34,35], and B cell homeostasis and tolerance [36,37].

Multiple sclerosis has often been classified as an autoimmune disease, and the obvious inflammatory response observed in the disease strongly supports this hypothesis. In light of previous studies implicating the TAM receptors in regulating both demyelination and autoimmune responses in both experimental animals and human MS lesions (for review, see ref. [38]), the present study provides strong evidence that **MERTK** represents a genuine MS susceptibility gene.

In conclusion, this candidate gene study has identified an association of MS with 12 SNPs in the **MERTK** gene that replicated in two independent cohorts of MS cases and controls, an association that is particularly compelling given the previous studies implicating TAM receptor signalling in demyelination and autoimmunity. Further fine mapping studies will be required to determine the causal variant or variants.

**Supporting Information**

Table S1 SNP associations of all directly genotyped TAM receptor and ligand genes in the top 300,000 SNPs of the discovery (GWAS) dataset.

**Acknowledgments**

We thank individuals in Australia and New Zealand for supporting this research. We thank Laura Johnson for technical assistance. Replication genotyping was conducted at the Murdoch Children’s Research Institute Sequenom Platform Facility.

**ANZGene Consortium.** Melanie Balio1, David R Booth2, Simon Broadley3, Matthew A Brown4, Brian L Browning4, Sharon R Brown5, Helmut Butzkueven6-8, William M Carroll9, Patrick Danoy10, Judith Field11,12, Simon J Foote13, Lyn Griffiths14, Robert N Heard15, Allan G Kerndode16-17, Trevor J Kilpatrick8, Jeanette Lechner-Scott19, 20, Pablo Moscato20, 21, Victoria M Perreau14, Rodney J Scott19,20,21, Mark Kew16, Graeme J Stewart1, Bruce V Taylor14, and James Wiley19 (Chair)

**Affiliations for Authors.** (AUS = Australia, NZ = New Zealand, VIC = Victoria, NSW = New South Wales, QLD = Queensland, South Australia = SA, TAS = Tasmania, WA = Western Australia).

1. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, AUS, 3050.
2. The Westmead Millenium Institute, Westmead, NSW, Australia 2145.
3. School of Medicine, Griffith University, QLD, Australia, 4222.
4. Department of Neurology, Gold Coast Hospital, QLD, Australia 4215.
5. The Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia 4102.
6. Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, OX3 7BN, UK.
7. Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
8. Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
9. Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
10. Florey Neuroscience Institutes, University of Melbourne, Melbourne, VIC, Australia.
11. Department of Neurology, Box Hill Hospital, VIC, Australia.
12. Sir Charles Gairdner Hospital, Nedlands, WA, AUS 6009.
13. Australian Neuromuscular Research Institute, Nedlands WA, AUS 6009.
14. Centre for Neuromuscular Research and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.
15. Centre for Neuroscience, University of Melbourne, VIC, Australia 3010.
16. Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia. 7001.
17. Genomics Research Centre, Griffith University, QLD, Australia 4222.
Author Contributions

Conceived and designed the experiments: GZMM JS TJK MDB JF. Performed the experiments: GZMM JF. Analyzed the data: GZMM JS JF. Contributed reagents/materials/analysis tools: GZMM JS TJK MDB JF. Wrote the paper: GZMM JS TJK MDB JF.
